Urinary Proteomics to Guide Early Intervention for Diabetes Complications
Background
Type 2 Diabetes Mellitus (T2DM) often leads to severe cardiovascular and renal complications, such as diabetic nephropathy and albuminuria. Early identification of patients at high risk or those who would benefit most from specific therapies is crucial for preventing disease progression. This study addresses the knowledge gap in using urinary proteomic signatures to personalize early intervention strategies for T2DM complications.
Study Design
Results
As an enrolling study, specific results are not yet available. However, the study aims to identify novel urinary proteomic biomarkers that can predict individual responses to Semaglutide, Finerenone, or Dapagliflozin in preventing cardiovascular and renal complications. Researchers will analyze changes in urinary protein profiles and correlate them with clinical outcomes like eGFR (estimated glomerular filtration rate) and albuminuria (excess albumin in urine). The primary goal is to determine if these proteomic signatures can guide personalized treatment decisions. This feasibility study seeks to determine if specific urinary proteomic patterns can predict the efficacy of established treatments in preventing complications of Type 2 Diabetes. The study expects to find biomarkers that could lead to more targeted interventions.
Why It Matters
The identification of predictive urinary biomarkers could revolutionize the management of Type 2 Diabetes by enabling truly personalized medicine. This approach could allow clinicians to select the most effective therapy for each patient, potentially preventing or delaying the onset of severe renal and cardiovascular complications. If successful, this research could pave the way for future clinical trials to validate these proteomic signatures as diagnostic tools and guide treatment selection in routine clinical practice. The findings from this feasibility study will inform the design of larger, potentially randomized, human trials.